Valitor leverages a Multivalent Polymer technology platform originating at U.C. Berkeley to create macromolecular therapeutics by combining multiple copies of bioactive molecules on individual biopolymer chains. The platform is designed to optimize pharmacokinetics, target engagement, tissue localization, therapeutic durability, and safety for challenging bioactives and indications. The company’s lead program is a novel anti-VEGF antibody for wet AMD that is positioned to enable twice-yearly treatment and is entering IND-enabling studies. Valitor intends to apply its technology broadly across ophthalmology and vision-threatening diseases to improve patient outcomes. The company is led by CEO Steven Lo, President & CSO Wesley Jackson, CDO William (Sandy) White, and founders Kevin Healy, Ph.D., and David Schaffer, Ph.D. Valitor recently closed a $28M Series B to support its development programs.

Total raised

$28M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2022